STAT3 and neoplasm: Our findings implied that miR-577 targeted and inactivated STAT3, and the use of the STAT3 agonist colivelin restrained the inhibition of miR-577 on NSCLC cells, including partially recovering tumor cell proliferation, migration, invasion and EMT.